Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum*
- 26 May 1997
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 61 (5) , 518-530
- https://doi.org/10.1016/s0009-9236(97)90132-6
Abstract
The population pharmacokinetics of atovaquone were examined in 458 black, Oriental, and Malay patients with acute Plasmodium falciparum malaria receiving atovaquone alone or concomitantly with other drugs. Oral clearance (CL/F) showed a 0.674 power relationship with weight and is similar in Oriental and Malay subjects but 58.5% lower in black subjects. On the basis of mean body weight, the population estimate of CL/F is 3.28, 8.49, and 9.13 L/hr in black, Oriental, and Malay subjects, respectively. The relationship between apparent volume of distribution (V area/F) and weight was linear and similar in all three races at 7.98 L/kg. The population estimate of V area/F is 345, 383, and 428 L in black, Oriental, and Malay subjects, respectively. The bioavailability of the high and low doses of atovaquone was similar. Neither CL/F nor V area/F were significantly affected by age, gender, and the coadministration with chloroguanide (proguanil), pyrimethamine, and tetracycline. Half-life (t1/2) showed a 0.326 power relationship with weight; thus, the population estimate of t1/2 in black, Oriental, and Malay subjects is 72.9, 31.3, and 32.5 hours, respectively. The final magnitudes of interpatient variability in CL/F and V area/F were 68% and 49%, respectively.Keywords
This publication has 21 references indexed in Scilit:
- Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquoneBritish Journal of Clinical Pharmacology, 1996
- Interactions of Atovaquone with Other Antimalarial Drugs against Plasmodium falciparum in VitroExperimental Parasitology, 1995
- The Effects of Antimalarials on the Plasmodium falciparum Dihydroorotate DehydrogenaseExperimental Parasitology, 1994
- Clinical Experience With Atovaquone: A New Drug for Treating Pneumocystis carinii PneumoniaThe Lancet Healthy Longevity, 1994
- Adverse Effects of Drugs Used in the Management of Opportunistic Infections Associated with HIV InfectionDrug Safety, 1994
- Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDSNew England Journal of Medicine, 1993
- A Preliminary Evaluation of 566C80 for the Treatment of Pneumocystis Pneumonia in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1991
- Safety and Pharmacokinetics of 566C80, a Hydroxynaphthoquinone with Anti-Pneumocystis carinii Activity: A Phase I Study in Human Immunodeficiency Virus (HIV)-Infected MenThe Journal of Infectious Diseases, 1991
- Racial Differences in Drug ResponseNew England Journal of Medicine, 1989
- Malaria — Resurgence, Resistance, and ResearchNew England Journal of Medicine, 1983